 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Liver tests were markedly abnormal in the hospital. The patient's doctors discontinued the rosiglitazone and gave the patient supportive care. Extensive tests showed no other cause for the liver damage. Blood levels of acetaminophen, which can cause liver damage, were very low. By the second day of hospitalization, the patient's symptoms resolved. His liver tests initially worsened, then slowly became normal over the next month.
SUMMARIES FOR PATIENTS
Liver Injury in a Person Taking the Diabetes Drug Rosiglitazone
18 January 2000 | Volume 132 Issue 2 | Page 121
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Hepatocellular Injury in a Patient Receiving Rosiglitazone. A Case Report" It is in the 18 January 1999 issue of Annals of Internal Medicine (volume 131, pages 121-124). The authors are J. Al-Salman, H. Arjomand, D.G. Kemp, and M. Mittal.
What is the problem and what is known about it so far?
High levels of blood sugar in diabetic patients contribute over time to complications such as blindness and kidney failure. The goal of diabetes treatment is therefore to keep blood sugar levels normal, but treatment often involves daily injections of insulin. The thiazolidinediones are a new class of diabetes drugs in pill form that lower blood sugar levels. Unfortunately, the first approved drug in this class, troglitazone, can cause severe liver damage in a small percentage of people. It is not yet known whether the second drug in this class, rosiglitazone, is associated with severe liver problems.
Why did the researchers do this particular study?
They observed liver damage in a patient taking rosiglitazone.
Who was studied?
A 61-year-old man who had been taking rosiglitazone 4 mg per day.
How was the study done?
The authors reviewed the patient's medical records.
What did the researchers find?
After taking rosiglitazone for 8 days, the patient had developed nausea, vomiting, decreased appetite, and abdominal pain, but he continued taking the drug. One week later, he was hospitalized with worsening symptoms. In addition to diabetes, the patient had lung disease and a history of alcoholism in the distant past. Eight months before this hospital admission, the patient had started taking a related diabetes drug, troglitazone, but stopped it because of abdominal pain. His liver function had been normal at that time. He had also taken repaglinide, a diabetes medication from a different class of drugs, starting 7 weeks before hospitalization but stopped it after 5 weeks because of nausea and dizziness. He then started rosiglitazone. The patient's other medications were acetaminophen (Tylenol) and drugs for his lung disease.
What were the limitations of the study?
It is impossible to know for sure in this single patient whether rosiglitazone caused the liver failure. The patient was also taking acetaminophen, which can cause liver damage at high doses, but blood levels of this drug were low; alcohol can also cause liver damage, but the patient denied drinking alcohol recently. The drugs that the patient was taking for his lung disease could have contributed to the damage, but they have not been associated previously with liver toxicity.
What are the implications of the study?
Liver damage may possibly occur in patients who take rosiglitazone. Patients taking this drug should have their liver tests watched carefully, and should discontinue the drug if symptoms develop.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  K. G. Tolman, V. Fonseca, A. Dalpiaz, and M. H. Tan Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease Diabetes Care, March 1, 2007; 30(3): 734 - 743. [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Spiller and T. S. Sawyer Toxicology of oral antidiabetic medications Am. J. Health Syst. Pharm., May 15, 2006; 63(10): 929 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR) Toxicol. Sci., April 1, 2006; 90(2): 269 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R Marcy, M. L Britton, and S. M Blevins Second-Generation Thiazolidinediones and Hepatotoxicity Ann. Pharmacother., September 1, 2004; 38(9): 1419 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. Lee Drug-Induced Hepatotoxicity N. Engl. J. Med., July 31, 2003; 349(5): 474 - 485. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sahi, C. B. Black, G. A. Hamilton, X. Zheng, S. Jolley, K. A. Rose, D. Gilbert, E. L. LeCluyse, and M. W. Sinz Comparative Effects of Thiazolidinediones on in Vitro P450 Enzyme Induction and Inhibition Drug Metab. Dispos., April 1, 2003; 31(4): 439 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Campbell and J. White Counseling Patients With Type 2 Diabetes and Insulin Resistance in the Outpatient Setting The Diabetes Educator, November 1, 2002; 28(6): 938 - 957. [PDF]
|
|
|
|
 |
|
 J D Tugwood and C T Montague Biology and toxicology of PPARg ligands Human and Experimental Toxicology, August 1, 2002; 21(8): 429 - 437. [Abstract] [PDF]
|
|
|
|
|
|
H. E. Lebovitz, M. Kreider, and M. I. Freed Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials: Evidence that rosiglitazone does not cause hepatic dysfunction Diabetes Care, May 1, 2002; 25(5): 815 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Parulkar, M. L. Pendergrass, R. Granda-Ayala, T. R. Lee, and V. A. Fonseca Nonhypoglycemic Effects of Thiazolidinediones Ann Intern Med, January 2, 2001; 134(1): 61 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Lenhard and W. B. Funk Failure to Develop Hepatic Injury From Rosiglitazone in a Patient With a History of Troglitazone-Induced Hepatitis Diabetes Care, January 1, 2001; 24(1): 168 - 169. [Full Text]
|
|
|
|
 |
|
 S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]
|
|
|
|
|
|
D. M. Hachey, M. P. O'Neil, and R. W. Force Isolated Elevation of Alkaline Phosphatase Level Associated with Rosiglitazone Ann Intern Med, November 7, 2000; 133(9): 752 - 752. [Full Text] [PDF]
|
|
|
|
|
|
R. S. Ravinuthala and U. Nori Rosiglitazone Toxicity Ann Intern Med, October 17, 2000; 133(8): 658 - 658. [Full Text] [PDF]
|
|
|
|
|
|
W. L. Isley and J. C. Oki Rosiglitazone and Liver Failure Ann Intern Med, September 5, 2000; 133(5): 393 - 393. [Full Text] [PDF]
|
|
|
|
|
|
E. Arioglu, J. Duncan-Morin, N. Sebring, K. I. Rother, N. Gottlieb, J. Lieberman, D. Herion, D. E. Kleiner, J. Reynolds, A. Premkumar, et al. Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes Ann Intern Med, August 15, 2000; 133(4): 263 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Campbell Management of Type 2 Diabetes in the Geriatric Patient Journal of Pharmacy Practice, August 1, 2000; 13(4): 263 - 276. [Abstract] [PDF]
|
|
|
|
|
|
Correction: Liver Injury and Rosiglitazone Ann Intern Med, August 1, 2000; 133(3): 237 - 237. [Full Text] [PDF]
|
|
|
|
 |
|
 Is Rosiglitazone Hepatotoxic, Too? Journal Watch Gastroenterology, April 1, 2000; 2000(401): 18 - 18. [Full Text]
|
|
|
|
 |
|
 Is Rosiglitazone Hepatotoxic, Too? Journal Watch (General), February 1, 2000; 2000(201): 1 - 1. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
